Myeloproliferative Neoplasms News

CHICAGO — Stephen Noga, MD, PhD, vice president of U.S. medical affairs for Takeda Oncology, spoke with HemOnc Today at ASCO Annual Meeting about several trials underway to assess agents in the company’s oncology pipeline.

Although a risk assessment tool can identify patients with cancer who are at risk for hepatitis B virus (HBV) reactivation from anticancer therapy, most patients will still require HBV testing, according to study results.

Patients with pre-existing B-cell clone gene who underwent treatment for myelofibrosis with ruxolitinib or other JAK1/2 inhibitors appeared to have a 16-fold increased risk for developing aggressive B-cell lymphoma, according to study findings published in Blood.

The FDA granted orphan drug designation to PU-H71 for the treatment of myelofibrosis.

Click here to read the Cover Story, “GVHD management improves, but questions remain about risk stratification, prophylaxis.”

The FDA approval of ibrutinib for adults with chronic graft-versus-host disease may herald a practice-changing breakthrough in the management of this posttransplant complication.

Cancer increased patients’ risk for subsequently developing diabetes, according to results of a cohort study conducted in South Korea.

Click here to read the Cover Story, “Deeper understanding of disease biology may improve outcomes in triple-negative breast cancer.”

Home-based care is the most traditional form of health care.

One of the most exciting aspects of clinical research is translating lab-based discoveries into tests and treatments that can be used in daily clinical practice.